References
- Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, Conley PB, Phillips DR, Hart MJ. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem 2005;280:24680–24689. doi:https://doi.org/10.1074/jbc.M413411200.
- Kauskot A, Di Michele M, Loyen S, Freson K, Verhamme P, Hoylaerts MF. A novel mechanism of sustained platelet aIIbB3 activation via PEAR1. Blood 2012;119:4056–4065. doi:https://doi.org/10.1182/blood-2011-11-392787.
- Kardeby C, Fälker K, Haining EJ, Criel M, Lindkvist M, Barroso R, Påhlsson P, Ljungberg LU, Tengdelius M, Rainger GE, et al. Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbα. Blood Adv 2019; 3:275–287. doi:https://doi.org/10.1182/bloodadvances.2018024950.
- Vandenbriele C, Sun Y, Criel M, Cludts K, Van Kerckhoven S, Izzi B, Vanassche T, Verhamme P, Hoylaerts MF. Dextran sulfate triggers platelet aggregation via direct activation of PEAR1. Platelets 2016;27:365–372. doi:https://doi.org/10.3109/09537104.2015.1111321.
- Sun Y, Vandenbriele C, Kauskot A, Verhamme P, Hoylaerts MF, Wright GJ. A human platelet receptor protein microarray identifies the high affinity immunoglobulin E receptor subunit α (FcεR1α) as an activating platelet endothelium aggregation receptor 1 (PEAR1) ligand. Mol Cell Proteomics 2015;14:1265–1274. doi:https://doi.org/10.1074/mcp.M114.046946.
- Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U, Martens L, Geiger J, Sickmann A, Zahedi RP. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012;120:e73–82. doi:https://doi.org/10.1182/blood-2012-04-416594.
- Criel M, Izzi B, Vandenbriele C, Liesenborghs L, Van Kerckhoven S, Lox M, Cludts K, Jones EAV, Vanassche T, Verhamme P, et al. Absence of Pear1 does not affect murine platelet function in vivo. Thromb Res 2016;146:76–83. doi:https://doi.org/10.1016/j.thromres.2016.08.026.
- Vandenbriele C, Kauskot A, Vandersmissen I, Criel M, Geenens R, Craps S, Luttun A, Janssens S, Hoylaerts MF, Verhamme P. Platelet endothelial aggregation receptor-1: A novel modifier of neoangiogenesis. Cardiovasc Res 2015;108:124–138. doi:https://doi.org/10.1093/cvr/cvv193.
- Zhan Q, Ma X, He Z. PEAR1 suppresses the proliferation of pulmonary microvascular endothelial cells via PI3K/AKT pathway in ALI model. Microvasc Res 2020;128:103941. doi:https://doi.org/10.1016/j.mvr.2019.103941.
- Chen Y, Ju L, Rushdi M, Ge C, Zhu C. Receptor-mediated cell mechanosensing. Mol Biol Cell 2017;28:3134–3155. doi:https://doi.org/10.1091/mbc.E17-04-0228.
- Kauskot A, Vandenbriele C, Louwette S, Gijsbers R, Tousseyn T, Freson K, Verhamme P, Hoylaerts MF. PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood 2013;121:5208–5217. doi:https://doi.org/10.1182/blood-2012-10-462887.
- Getz TM, Kanth Manne B, Buitrago L, Mao Y, Kunapuli SP. Dextran sulphate induces fibrinogen receptor activation through a novel Syk-independent PI-3 kinase-mediated tyrosine kinase pathway in platelets. Thromb Haemost 2013;109:1131–1140. doi:https://doi.org/10.1160/TH12-09-0645.
- Zeiler M, Moser M, Mann M. Copy number analysis of the murine platelet proteome spanning the complete abundance range. Mol Cell Proteomics 2014;13:3435–3445. doi:https://doi.org/10.1074/mcp.M114.038513.
- Dunster JL, Unsworth A, Bye A, Haining EJ, Di Y, Pallini C, Pike J, Hardy A, Nieswandt B, Watson S, Poulter N, et al. Interspecies differences in protein expression do not impact the spatiotemporal regulation of GPVI mediated activation. J. Thromb. Haemost. 2020;18:485–496
- Trevisan AJ, Bauer MB, Brindley RL, Currie KPM, Carter BD. Jedi-1 deficiency increases sensory neuron excitability through a non-cell autonomous mechanism. Sci Rep 2020;10:1–15. doi:https://doi.org/10.1038/s41598-020-57971-2.
- Faraday N, Yanek LR, Yang XP, Mathias R, Herrera-Galeano JE, Suktitipat B, Qayyum R, Johnson AD, Chen M-H, Tofler GH, et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 2011;118:3367–3375. doi:https://doi.org/10.1182/blood-2010-11-320788.
- Pi L, Xu Y, Fu L, Zhang L, Liu Y, Zhou H, Che D, Gu X. A PEAR1 polymorphism (rs12041331) is associated with risk of coronary artery aneurysm in Kawasaki disease. Ann Hum Genet 2019;83:54–62. doi:https://doi.org/10.1111/ahg.12285.
- Stimpfle F, Bauer M, Rath D, Schaeffeler E, Schwab M, Gawaz M, Winter S, Geisler T. Variants of PEAR1 are associated with outcome in patients with ACS and stable CAD undergoing PCI. Front Pharmacol 2018;9. doi:https://doi.org/10.3389/fphar.2018.00490.
- Herrera-Galaeno JE, Becker DM, Wilson AF, Yanek LR, Bray P, Vaidya D, Faraday N, Becker LC. A novel variant in the platelet endothelial aggregation Receptor-1 gene is associated with increased platelet aggregability. Arter Thromb Vascl Biol 2008;28:1484–1490. doi:https://doi.org/10.1161/ATVBAHA.108.168971.A.
- Jones C, Bray S, Garner S, Stephens J, de Bono B, Angenent WGJ, Bentley D, Burns P, Coffey A, Deloukas P, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009;114:1405–1417. doi:https://doi.org/10.1182/blood-2009-02-202614.
- Fu Y, Sun S, Liang J, Liu S, Jiang Y, Xu L, Mei J. PEAR1 gene polymorphism in a Chinese pedigree with pulmonary thromboembolism. Med (United States) 2016;95:e5687. doi:https://doi.org/10.1097/MD.0000000000005687.
- Xiang Q, Cui Y, Zhao X, Zhao N. Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics 2013;14:1179–1189. doi:https://doi.org/10.2217/pgs.13.108.
- Garman SC, Kinet JP, Jardetzky TS. Crystal structure of the human high-affinity IgE receptor. Cell 1998;95:951–961. doi:https://doi.org/10.1016/S0092-8674(00)81719-5.
- Fitton J, Stringer D, Karpiniec S. Therapies from fucoidan: an update. Mar Drugs 2015;13:5920–5946. doi:https://doi.org/10.3390/md13095920.
- Tengdelius M, Kardeby C, Fälker K, Griffith M, Påhlsson P, Konradsson P, Grenegård M. Fucoidan-mimetic glycopolymers as tools for studying molecular and cellular responses in human blood platelets. Macromol Biosci 2017;17:1–9. doi:https://doi.org/10.1002/mabi.201600257.
- Manne BK, Getz TM, Hughes CE, Alshehri O, Dangelmaier C, Naik UP, Watson SP, Kunapuli SP. Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2). J Biol Chem 2013;288:7717–7726. doi:https://doi.org/10.1074/jbc.M112.424473.
- Ale MT, Maruyama H, Tamauchi H, Mikkelsen JD, Meyer AS. Fucose-containing sulfated polysaccharides from brown apoptosis by activation of caspase-3 in vitro 2011:2605–2621. 10.3390/md9122605.
- Rioux LE, Turgeon SL, Beaulieu M. Effect of season on the composition of bioactive polysaccharides from the brown seaweed Saccharina longicruris. Phytochemistry 2009;70:1069–1075. doi:https://doi.org/10.1016/j.phytochem.2009.04.020.
- Klemm D, Heinze T, Liebert T, Heublein B, Hornig S. Functional polymers based on dextran BT - polysaccharides II. Polysaccharides II 2006;205:199–291.
- Gallagher JT. Heparin - A century of progress. Handb Exp Pharmacol 2012;207:347–360. doi:https://doi.org/10.1007/978-3-642-23056-1.
- Wang Z, Zhang F,S, Dordick J,J, Linhardt R. Molecular mass characterization of glycosaminoglycans with different degrees of sulfation in bioengineered heparin process by size exclusion chromatography. Curr Anal Chem 2012;8:506–511. doi:https://doi.org/10.2174/157341112803216753.
- Caterson B, Melrose J. Keratan sulfate, a complex glycosaminoglycan with unique functional capability. Glycobiology 2018;28:182–206. doi:https://doi.org/10.1093/glycob/cwy003.
- Hachim D, Whittaker TE, Kim H, Stevens MM. Glycosaminoglycan-based biomaterials for growth factor and cytokine delivery: making the right choices. J Control Release 2019;313:131–147. doi:https://doi.org/10.1016/j.jconrel.2019.10.018.
- Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008;72:455–482. doi:https://doi.org/10.1111/j.1747-0285.2008.00741.x.
- Funderburgh JL. Keratan Sulfate Biosynthesis. IUBMB Life 2002;54:187–194. doi:https://doi.org/10.1080/15216540214932.
- Pomin VH, Vignovich WP, Gonzales AV, Vasconcelos AA, Mulloy B. Galactosaminoglycans: medical applications and drawbacks. Molecules 2019;24:1–33. doi:https://doi.org/10.3390/molecules24152803.
- Liu J, Li J, Arnold K, Pawlinski R, Key NS. Using heparin molecules to manage COVID‐2019. Res Pract Thromb Haemost 2020;4:518–523. doi:https://doi.org/10.1002/rth2.12353.
- Oguma T, Toyoda H, Toida T, Imanari T. Analytical method for keratan sulfates by high-performance liquid chromatography/turbo-ionspray tandem mass spectrometry. Anal Biochem 2001;290:68–73. doi:https://doi.org/10.1006/abio.2000.4940.
- Lin L, Yang L, Chen J, Zhou L, Li S, Gao N, Zhao J. High-molecular-weight fucosylated glycosaminoglycan induces human platelet aggregation depending on αIIbβ3 and platelet secretion. Platelets 2020;00:1–9. doi:https://doi.org/10.1080/09537104.2020.1820976.
- Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of heparin and related drugs. Pharmacol Rev 2015;68:76–141. doi:https://doi.org/10.1124/pr.115.011247.
- Foster AB, Huggard AJ. The chemistry of heparin. Adv Carbohydr Chem 1955;10:335–368. doi:https://doi.org/10.1016/S0096-5332(08)60397-5.
- Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, Kusumoto S, Blystone SD, Suda Y. Heparin modulates integrin function in human platelets. J Vasc Surg 2001;33:587–594. doi:https://doi.org/10.1067/mva.2001.112696.
- Yagi M, Murray J, Strand K, Blystone S, Interlandi G, Suda Y, Sobel M. Heparin modulates the conformation and signaling of platelet integrin αiIbβ3. Thromb Res 2012;129:743–749. doi:https://doi.org/10.1016/j.thromres.2011.11.054.
- Vögtle T, Sharma S, Mori J, Nagy Z, Semeniak D, Scandola C, Geer MJ, Smith CW, Lane J, Pollack S, et al. Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B. Elife 2019;8:1–43. doi:https://doi.org/10.7554/elife.46840.
- Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ. Heparin promotes platelet responsiveness by potentiating alphaIIb beta3-mediated outside-in signaling. Blood 2011;117:4946–4952. doi:https://doi.org/10.1182/blood-2010-09-307751.An.
- Mulloy B, Lever R, Page CP. Mast cell glycosaminoglycans. Glycoconj J 2017;34:351–361. doi:https://doi.org/10.1007/s10719-016-9749-0.
- Korpetinou A, Skandalis SS, Labropoulou VT, Smirlaki G, Noulas A, Karamanos NK, Teocharis AD. Serglycin: at the crossroad of inflammation and malignancy. Front Oncol 2014;4:JAN:1–12. doi:https://doi.org/10.3389/fonc.2013.00327.
- Woulfe DS, Lilliendahl JK, August S, Rauova L, Kowalska MA, Åbrink M, Pejler G, White JG, Schick BP. Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood 2008;111:3458–3467. doi:https://doi.org/10.1182/blood-2007-07-104703.
- Mummery RS, Rider CC. Characterization of the heparin-binding properties of IL-6. J Immunol 2000;165:5671–5679. doi:https://doi.org/10.4049/jimmunol.165.10.5671.
- Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992;22:3027–3031. doi:https://doi.org/10.1002/eji.1830221139.
- Tengdelius M, Lee CJ, Grenegård M, Griffith M, Påhlsson P, Konradsson P. Synthesis and biological evaluation of fucoidan-mimetic glycopolymers through cyanoxyl-mediated free-radical polymerization. Biomacromolecules 2014;15:2359–2368. doi:https://doi.org/10.1021/bm5002312.
- Oduah EI, Linhardt RJ, Sharfstein ST. Heparin: past, present, and future. Pharmaceuticals 2016;9:1–12. doi:https://doi.org/10.3390/ph9030038.
- Ponomaryov T, Payne H, Fabritz L, Wagner DD, Brill A. Mast cells granular contents are crucial for deep vein thrombosis in mice. Circ Res 2017;121:941–950. doi:https://doi.org/10.1161/CIRCRESAHA.117.311185.
- He Z, Ma C, Yu T, Song J, Leng J, Gu X, Li J. Activation mechanisms and multifaceted effects of mast cells in ischemia reperfusion injury. Exp Cell Res 2019;376:227–235. doi:https://doi.org/10.1016/j.yexcr.2019.01.022.